Tourmaline Bio, Inc.

Tourmaline Bio, Inc.

TRML·NASDAQ

$47.98

+0.0000%
HealthcareBiotechnology

Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune diseases. It develops medicines and therapies for the Atherosclerotic cardiovascular disease (ASCVD) and Thyroid Eye Disease (TED). The company was incorporated in 2021 and is based in New York, New York.

At a Glance

Live Snapshot
Market Cap$1.23B
EPS-2.8900
P/E Ratio-7.02
Earnings Date04/30/2026

trml

Net Cash Provided by Financing Activities

Last Annual Value

161.35M

3-Year CAGR

6%

5-Year CAGR

35%

10-Year CAGR

16%

Tourmaline Bio, Inc.

Tourmaline Bio, Inc. Competitors Analysis of Net Cash Provided by Financing Activities

TRML · NASDAQ
CompanyNet Cash Provided by Financing Activities
CAGR 3Y
CAGR 5Y
CAGR 10Y
161.35M
1.0%3.3%N/A 
257.03M
317.1%10.2%N/A
280.12M
28.0%25.6%38.6%
218.87M
-2.2%N/AN/A
247.66M
42.5%38.2%N/A
PGEN logo
Precigen, Inc.
NASDAQ:PGEN
90.05M
44.9%-5.8%22.3%
1.60M
-64.1%-66.6%N/A
13.68M
-62.7%-35.1%-12.9%
743.51M
160.7%40.8%N/A
Tourmaline Bio, Inc.

Tourmaline Bio, Inc. Fair Value Envelope

TRML · NASDAQ

Our analysis suggests that TRML has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $47.98, this represents a potential HIDDEN relative to our calculated worth for Tourmaline Bio, Inc..

Intrinsic Value
Current Price: $47.98